Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Melanoma Research
|
October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study
Joshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
European Journal of Immunology
|
July 19, 2012
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients
Simone M Goldinger, Reinhard Dummer, Petra Baumgaertner, et al.
Melanoma Research
|
May 17, 2017
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Joanna Mangana, Phil F Cheng, Corina Kaufmann, et al.
Genome Biology
|
April 18, 2015
Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
Phil F Cheng, Olga Shakhova, Daniel S Widmer, et al.
Pharmacology Research & Perspectives
|
March 3, 2015
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Simone M Goldinger, Jeannine Rinderknecht, Reinhard Dummer, et al.
Plos One
|
October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
Cancer Medicine
|
July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
Benjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Immunology Research
|
November 15, 2018
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Sabrina A Hogan, Anaïs Courtier, Phil F Cheng, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati, Katy K Tsai, Simone M Goldinger, et al.
Melanoma Research
|
October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study
Joshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
European Journal of Immunology
|
July 19, 2012
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients
Simone M Goldinger, Reinhard Dummer, Petra Baumgaertner, et al.
Melanoma Research
|
May 17, 2017
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Joanna Mangana, Phil F Cheng, Corina Kaufmann, et al.
Genome Biology
|
April 18, 2015
Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
Phil F Cheng, Olga Shakhova, Daniel S Widmer, et al.
Pharmacology Research & Perspectives
|
March 3, 2015
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Simone M Goldinger, Jeannine Rinderknecht, Reinhard Dummer, et al.
Plos One
|
October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
Cancer Medicine
|
July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
Benjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Immunology Research
|
November 15, 2018
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Sabrina A Hogan, Anaïs Courtier, Phil F Cheng, et al.
Page
of 7